STAT3 and inflammatory bowel disease: To further clarify the mechanism of action of YHKJ combined with SASP in the treatment of UC, we performed KEGG network pharmacologyanalysis and found that STAT3, a core target, is involved in the pathological changes in UC in the inflammatory bowel disease pathway.